70
Participants
Start Date
December 31, 2015
Primary Completion Date
November 16, 2016
Study Completion Date
November 16, 2016
Omalizumab
Omalizumab is an anti-Immunoglobulin E antibody injection and will be administered per product insert from weeks 0 through 16 of the study.
Food Flour Buildup
Food flours identified as allergic (based on food challenge), will be introduced at week 8. The food dose will be escalated every 2 weeks up to 2000 milligrams of each of the food flours. Subjects are required to reach 300 milligrams at week 16 to continue to week 30. Subjects must tolerate 2000 milligrams per food by week 28 in order to be randomized.
Mt. Sinai, Icahn School of Medicine, New York
Children's Hospital of Philadelphia, Philadelphia
Cincinnati Children's Hospital Medical Center, Cincinnati
Lurie Children's Hospital, Northwestern University, Chicago
Children's Hospital of Los Angeles, Los Angeles
Sean N. Parker Center for Allergy Research at Stanford University, Mountain View
Northwest Asthma & Allergy Center, Seattle
Icahn School of Medicine at Mount Sinai
OTHER
Children's Hospital of Philadelphia
OTHER
Ann & Robert H Lurie Children's Hospital of Chicago
OTHER
Children's Hospital Medical Center, Cincinnati
OTHER
Children's Hospital Los Angeles
OTHER
University of Washington
OTHER
Kari Christine Nadeau
OTHER